urea has been researched along with Adenoma, Prostatic in 16 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (68.75) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Byard, RW | 1 |
| Farahani, H | 1 |
| Alaee, M | 1 |
| Amri, J | 1 |
| Baghinia, MR | 1 |
| Rafiee, M | 1 |
| KOSTENKO, SN | 1 |
| FOX, M | 1 |
| PARSONS, FM | 1 |
| Chiu, G | 1 |
| Li, S | 1 |
| Connolly, PJ | 1 |
| Pulito, V | 1 |
| Liu, J | 1 |
| Middleton, SA | 1 |
| Kafetz, K | 1 |
| Upadhyay, L | 1 |
| Tripathi, K | 1 |
| Kulkarni, KS | 1 |
| Willden, EG | 1 |
| Robinson, MR | 1 |
| van Sande, M | 1 |
| Van Camp, K | 1 |
| Di Salle, E | 1 |
| Briatico, G | 1 |
| Giudici, D | 1 |
| Ornati, G | 1 |
| Nesi, M | 1 |
| Panzeri, A | 1 |
| Castro, JE | 1 |
| Griffiths, HJ | 1 |
| Edwards, DE | 1 |
| Vaughan, ED | 1 |
| Gillenwater, JY | 1 |
| Singh, M | 1 |
| Tresidder, GC | 1 |
| Blandy, JP | 1 |
| Lissoos, I | 1 |
| Aubrey, DA | 1 |
| Peeling, WB | 1 |
| Crivda, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Research on Benefit of Umooze as Add-on Therapy in Benign Prostatic Hyperplasia[NCT02313233] | 41 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
It's 7- item urinary symptom severity scale. The answers are assigned points from 0 to 5, indicating increasing severity. The total score can therefore range from 0 to 35 points. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| International prostate symptom score | Difference in IPSS between V1 and V6 | |
| Placebo | 13.6 | -5.94 |
| Umooze | 9.83 | -3.39 |
It's 7- item urinary symptom severity scale. The answers are assigned points from 0 to 5, indicating increasing severity. The total score can therefore range from 0 to 35 points. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| International prostate symptom score | Difference in IPSS between V1 and V6 | |
| Placebo | 14.33 | -4.33 |
| Umooze | 11.00 | -9.50 |
It's used to determine the degree of urinary difficulty. (NCT02313233)
Timeframe: 56 days
| Intervention | ml/ sec (Mean) | |
|---|---|---|
| Qmax | Difference of Qmax between V1 and V6 | |
| Placebo | 12.72 | 2.49 |
| Umooze | 14.4 | 2.88 |
The PVR urine test measures the amount of urine left in the bladder after urination. (NCT02313233)
Timeframe: 56 days
| Intervention | ml (Mean) | |
|---|---|---|
| Post- Void Residual Volume (PVR) | Difference of PVR between V1 and V6 | |
| Placebo | 67.2 | 14.8 |
| Umooze | 35.3 | -8.39 |
It's related to progression of benign prostatic hyperplasia (BPH). (NCT02313233)
Timeframe: 56 days
| Intervention | cm^3 (Mean) | |
|---|---|---|
| Prostate Volume | Difference of prostate volume between V1 and V6 | |
| Placebo | 38.2 | -1.33 |
| Umooze | 29.1 | -8.17 |
Serum PSA test measures the amount of prostate- specific antigen in the blood. As a man's prostate enlarges with age, the amount of PSA in the blood normally increases. (NCT02313233)
Timeframe: 56 days
| Intervention | ng/ml (Mean) | |
|---|---|---|
| Prostate- specific Antigen (PSA) | Difference of PSA between V1 and V6 | |
| Placebo | 2.22 | 0.26 |
| Umooze | 1.67 | 0.14 |
The Quality of Life (QoL) is a single question with scores of 0~6 point and corresponding to the assessment index ranging from delighted to terrible. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Quality of Life (QoL) | Difference of QoL between V1 and V6 | |
| Placebo | 3.27 | -0.09 |
| Umooze | 2.73 | -0.82 |
The QoL index is a single question with scores of 0~6 point and corresponding to the assessment index ranging from delighted to terrible. (NCT02313233)
Timeframe: 56 days
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Quality-of-Life (QoL) | Difference of QoL between V1 and V6 | |
| Placebo | 3.22 | -0.56 |
| Umooze | 2.72 | -0.61 |
1 review available for urea and Adenoma, Prostatic
| Article | Year |
|---|---|
Renal impairment in the elderly: a review.
Topics: Acute Kidney Injury; Aged; Aging; Creatinine; Dehydration; Female; Glomerular Filtration Rate; Heart | 1983 |
3 trials available for urea and Adenoma, Prostatic
| Article | Year |
|---|---|
A study of prostane in the treatment of benign prostatic hyperplasia.
Topics: Aged; Creatinine; Glomerular Filtration Rate; Humans; Male; Middle Aged; Plant Extracts; Prostate-Sp | 2001 |
Plasma zinc legels in prostatic disease.
Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Clinical Trials as Topic; Creatinine; Female; H | 1975 |
A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy.
Topics: Clinical Trials as Topic; Cystoscopy; Factor Analysis, Statistical; Humans; Male; Placebos; Prostati | 1971 |
12 other studies available for urea and Adenoma, Prostatic
| Article | Year |
|---|---|
Obstructive uropathy and unexpected death.
Topics: Aged; Cachexia; Creatinine; Death, Sudden; Dilatation, Pathologic; Humans; Hydronephrosis; Male; Pro | 2020 |
Serum and Saliva Concentrations of Biochemical Parameters in Men with Prostate Cancer and Benign Prostate Hyperplasia.
Topics: beta 2-Microglobulin; Biomarkers; Case-Control Studies; Creatine Kinase, BB Form; Creatinine; Down-R | 2020 |
[Urea clearance as a kidney function test in prostate adenoma].
Topics: Adenoma; Humans; Kidney Function Tests; Male; Prostatic Hyperplasia; Urea; Urography | 1962 |
INDICATIONS FOR HAEMODIALYSIS IN ADVANCED URAEMIC PROSTATIC OBSTRUCTION.
Topics: Blood Chemical Analysis; Dialysis; Geriatrics; Humans; Kidney; Kidneys, Artificial; Male; Preoperati | 1964 |
(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Prostatic Hyperplasia; Receptors, Adrenergic, | 2008 |
Amino acids of the Krebs-Henseleit cycle of median and lateral lobes in human benign prostatic hypertrophy.
Topics: Amino Acids; Arginine; Citrulline; Humans; Male; Ornithine; Prostate; Prostatic Hyperplasia; Protein | 1978 |
17 beta-acylurea derivatives of 4-azasteroids as inhibitors of testosterone 5 alpha-reductase.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aging; Androstanes; Animals; Az | 1992 |
Diagnosis, characterization and management of post-obstructive diuresis.
Topics: Aged; Creatinine; Desoxycorticosterone; Diuresis; Edema; Heart Failure; Humans; Hypertension; Infusi | 1973 |
The evaluation of transurethral resection for benign enlargement of the prostate.
Topics: Adult; Age Factors; Aged; Epididymitis; Humans; Male; Methods; Middle Aged; Prostatectomy; Prostatic | 1973 |
Simple prostatic hyperplasia in the Bantu.
Topics: Adult; Aged; Black People; Hematuria; Hernia, Inguinal; Humans; Male; Middle Aged; Prostatectomy; Pr | 1973 |
Carcinoma of the prostate. A retrospective analysis of conventional management in 110 cases.
Topics: Acid Phosphatase; Age Factors; Aged; Blood Sedimentation; Diagnosis, Differential; Estrogens; Hemogl | 1973 |
[Forced diuresis in the immediate postoperative period after prostatic adenomectomy].
Topics: Diuretics; Furosemide; Humans; Male; Postoperative Care; Prostatic Hyperplasia; Urea; Water-Electrol | 1974 |